Innate Immune Mechanisms Contributing to Cancer Growth in Obesity
Innate Immune Mechanisms Contributing to Cancer Growth in Obesity
批准号:
10278250
负责人:
EDGAR G. ENGLEMAN
金额:
$52.61万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-07-01 至 2026-06-30
关键词:
AcidityAcidsAdultAffectAutomobile DrivingBiological AssayBlocking AntibodiesBlood donorCTLA4 geneCancer EtiologyCell physiologyCellsColon CarcinomaColorectal CancerCyclic AMPCyclic AMP-Dependent Protein KinasesDataDevelopmentDietDiseaseExhibitsFlow CytometryFrequenciesGenus HippocampusGrowthHigh Fat DietHumanImmuneImmune responseImpairmentInflammatory ResponseKRASG12DLipidsMC38Malignant NeoplasmsMediator of activation proteinModelingMusNon obeseObese MiceObesityOleic AcidsOutcomeOverweightPatientsPlayPopulationPredispositionPrimary carcinoma of the liver cellsProductionPrognosisRiskRoleSamplingSignal TransductionSocietiesSolid NeoplasmTNF geneTestingTherapeutic EffectTriglyceridesTumor ImmunityTumor-associated macrophagesUnited Statesanti-PD-1/PD-L1basecancer therapycell typecolon cancer patientscolon growthcytokinediet-induced obesitydietaryfatty acid oxidationhuman dataimmune checkpoint blockadeinnate immune mechanismsmacrophagemelanomamortalitymouse modelneoplasm immunotherapyneoplastic cellnovelobese patientsobesogenicoverexpressionrapid growthreceptorresponsesubcutaneoustherapy outcometumortumor growthtumor metabolismtumor microenvironment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
Colorectal cancer (CRC) is the second leading cause of cancer mortality in the United States, and obesity, which
affects 40% of the population, not only increases the risk of developing CRC, but also increases CRC mortality
through unknown mechanisms. Our preliminary studies demonstrate that CRC grows faster in mice rendered
obese through a high fat diet (HFD), and that the tumor associated macrophages (TAMs) in these mice exhibit
higher expression of the acid sensing receptor, GPR65, which is known to dampen the immune response.
Moreover, in HFD-induced obese mice lacking GRP65, TAMs secrete more TNF-α and tumor growth is retarded.
Given that TAMs but not normal tissue macrophages of obese mice exhibit increased GPR65, we examined the
pH of the tumors in these mice and found them to be more acidic. On the basis of these findings, we hypothesize
that excess lipids in the HFD alter tumor cell metabolism resulting in increased acid production, which potentiates
GPR65 expression and signaling in TAMs, causing them to become immunosuppressive and promote tumor
growth. To test this hypothesis we will pursue the following specific aims: 1) Determine the contribution of
GPR65 signaling to TAM function and CRC growth under conditions of obesity by determining if the cAMP-
PKA signaling axis, which functions downstream of GPR65, is activated in TAMs of obese mice and controls
TNF-α production. We will also analyze GPR65 expression and the cytokine secretion capacity of macrophages
from healthy blood donors and TAMs in CRC samples from non-obese and obese patients; 2) Identify the
mechanism by which HFD promotes GPR65 signaling in CRC TAMs by testing the ability of HFD and oleic
acid, a dietary triglyceride that is highly enriched in HFD tumors, to alter the oxidative potential, fatty acid
oxidation capacity and acid production of human tumor cells via flow cytometry, CyTOF and Seahorse assays.
We will also determine if a high-oleic-acid diet is sufficient to modify GPR65 expression and cytokine production
by TAMs, and examine if tumor acidity is required for the blunted inflammatory response of TAMs; and verify the
role of GPR65 in human macrophages and 3) Assess the effects of targeting GPR65 for tumor
immunotherapy in obese and nonobese mice with CRC and other tumor types, namely hepatocellular
carcinoma and melanoma, and assess the effects of checkpoint blocking antibodies on tumor growth and anti-
tumor immunity in GPR65+ and GPR-/- mice bearing these tumors. The results of these studies are expected to
not only reveal a critical mechanism responsible for accelerated tumor growth in the setting of obesity, but also
identify a novel target for the treatment of these cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 1 Mouse Models Analysis
-
批准号:10729466
-
项目类别:
-
资助金额:$56.36万
-
财政年份:2023
-
负责人:EDGAR G. ENGLEMAN
-
依托单位:
Systems Biology of Tumor-Immune-Stromal Interactions in Metastatic Progression
-
批准号:10729464
-
项目类别:
-
资助金额:$191.91万
-
财政年份:2023
-
负责人:EDGAR G. ENGLEMAN
-
依托单位:
Project 3: Impact of tumor genetics on PDAC immunobiology and responses to macrophage-targeted immunotherapy
-
批准号:10704089
-
项目类别:
-
资助金额:$42.16万
-
财政年份:2021
-
负责人:EDGAR G. ENGLEMAN
-
依托单位:
Targeting Lymph Node Dependent Immune Tolerance in Cancer
-
批准号:10210557
-
项目类别:
-
资助金额:$53.17万
-
财政年份:2021
-
负责人:EDGAR G. ENGLEMAN
-
依托单位:
Innate Immune Mechanisms Contributing to Cancer Growth in Obesity
-
批准号:10654802
-
项目类别:
-
资助金额:$48.55万
-
财政年份:2021
-
负责人:EDGAR G. ENGLEMAN
-
依托单位:
Innate Immune Mechanisms Contributing to Cancer Growth in Obesity
-
批准号:10430268
-
项目类别:
-
资助金额:$48.55万
-
财政年份:2021
-
负责人:EDGAR G. ENGLEMAN
-
依托单位:
Project 3: Impact of tumor genetics on PDAC immunobiology and responses to macrophage-targeted immunotherapy
-
批准号:10456771
-
项目类别:
-
资助金额:$42.16万
-
财政年份:2021
-
负责人:EDGAR G. ENGLEMAN
-
依托单位:
Innate Immune Mechanisms Contributing to Cancer Growth in Obesity
-
批准号:10706825
-
项目类别:
-
资助金额:$23.18万
-
财政年份:2021
-
负责人:EDGAR G. ENGLEMAN
-
依托单位:
Targeting Lymph Node Dependent Immune Tolerance in Cancer
-
批准号:10366092
-
项目类别:
-
资助金额:$52.36万
-
财政年份:2021
-
负责人:EDGAR G. ENGLEMAN
-
依托单位:
Project 3: Impact of tumor genetics on PDAC immunobiology and responses to macrophage-targeted immunotherapy
-
批准号:10187127
-
项目类别:
-
资助金额:$44.33万
-
财政年份:2021
-
负责人:EDGAR G. ENGLEMAN
-
依托单位:
Targeting Lymph Node Dependent Immune Tolerance in Cancer
-
批准号:10599941
-
项目类别:
-
资助金额:$52.74万
-
财政年份:2021
-
负责人:EDGAR G. ENGLEMAN
-
依托单位:
Effects of Maternal Obesity on Offspring Immune System
-
批准号:9913383
-
项目类别:
-
资助金额:$19.9万
-
财政年份:2019
-
负责人:EDGAR G. ENGLEMAN
-
依托单位:
Effects of FLASH Radiation on Cancer and the Immune Response
-
批准号:10599538
-
项目类别:
-
资助金额:$10.51万
-
财政年份:2019
-
负责人:EDGAR G. ENGLEMAN
-
依托单位:
Effects of FLASH Radiation on Cancer and the Immune Response
-
批准号:10429937
-
项目类别:
-
资助金额:$48.32万
-
财政年份:2019
-
负责人:EDGAR G. ENGLEMAN
-
依托单位:
Effects of FLASH Radiation on Cancer and the Immune Response
-
批准号:10188463
-
项目类别:
-
资助金额:$49.3万
-
财政年份:2019
-
负责人:EDGAR G. ENGLEMAN
-
依托单位:
Effects of FLASH Radiation on Cancer and the Immune Response
-
批准号:10665654
-
项目类别:
-
资助金额:$48.32万
-
财政年份:2019
-
负责人:EDGAR G. ENGLEMAN
-
依托单位:
Targeting Dectin-2 on Tumor-associated Macrophages for the Treatment of Cancer
-
批准号:10401797
-
项目类别:
-
资助金额:$41.97万
-
财政年份:2018
-
负责人:EDGAR G. ENGLEMAN
-
依托单位:
Targeting Dectin-2 on Tumor-associated Macrophages for the Treatment of Cancer
-
批准号:9918925
-
项目类别:
-
资助金额:$43.48万
-
财政年份:2018
-
负责人:EDGAR G. ENGLEMAN
-
依托单位:
Role of Dendritic Cells in Mixed Chimerism and Tolerance
-
批准号:9223664
-
项目类别:
-
资助金额:$39.91万
-
财政年份:2015
-
负责人:EDGAR G. ENGLEMAN
-
依托单位:
Applicability of Mouse Breast Cancer Models to Tumor-Immune Network Investigation
-
批准号:9121492
-
项目类别:
-
资助金额:$57.05万
-
财政年份:2015
-
负责人:EDGAR G. ENGLEMAN
-
依托单位:
国内基金
海外基金
登录
查看更多内容
具有抗癌活性的天然产物金霉酸(Aureolic acids)全合成与选择性构建2-脱氧糖苷键
-
批准号:22007039
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:王黎明
-
依托单位:
海洋放线菌来源聚酮类化合物Pteridic acids生物合成机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2019
-
负责人:朱义广
-
依托单位:
手性Lewis Acids催化的分子内串联1,5-氢迁移/环合反应及其在构建结构多样性手性含氮杂环化合物中的应用
-
批准号:21372217
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:袁伟成
-
依托单位:
对空气稳定的新型的有机金属Lewis Acids催化剂制备、表征与应用研究
-
批准号:21172061
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2011
-
负责人:许新华
-
依托单位:
钛及含钛Lewis acids促臭氧/过氧化氢体系氧化性能的广普性、高效性及其机制
-
批准号:21176225
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:童少平
-
依托单位:
基于Zip Nucleic Acids引物对高度降解和低拷贝DNA检材的STR分型研究
-
批准号:81072511
-
项目类别:面上项目
-
资助金额:31.0万元
-
批准年份:2010
-
负责人:严江伟
-
依托单位:
海洋天然产物Makaluvic acids 的全合成及其对南海鱼虱存活的影响
-
批准号:30660215
-
项目类别:地区科学基金项目
-
资助金额:21.0万元
-
批准年份:2006
-
负责人:王世范
-
依托单位: